Olive, whose AI-powered bot automates healthcare admin tasks, has raised $106M led by General Catalyst and Drive Capital, bringing total raised to $222M
Carrie Ghose / Columbus Business Journal : Tweets: @columbusbiz1st Tweets: Columbus Biz First / @columbusbiz1st : Five months after raising $52M in VC, Columbus health AI maker Olive has raised another $106M toward a goal of landing all 5,000 U.S. hospitals as clients. https://www.bizjournals.com/ ...
Context & Ripple Effects
Five months after an $51M round led by General Catalyst in April 2020, Columbus-based Olive doubled down on its land-grab for U.S. hospital administration work, with General Catalyst returning alongside Drive Capital and a stated goal of signing all 5,000 U.S. hospitals. The raise sits at the start of a funding arc the corpus traces end-to-end: a $225.5M Tiger Global round at a $1.5B valuation that December, then $400M at $4B by mid-2021.
The same coverage also records how that arc ended — a 450-person layoff in 2022 and a planned shutdown with parts sold to Waystar and Humata Health — which makes this September 2020 raise less a growth story than the inflection point where Olive's capital intake began outrunning its hospital traction.
First-order effects
- General Catalyst and Drive Capital's $106M gives Olive the runway to chase its stated target of all 5,000 U.S. hospitals, directly pressuring incumbent hospital IT vendors and manual revenue-cycle staffing budgets at those systems.
- The round validates healthcare admin automation as a fundable category in late 2020, drawing Tiger Global into the next tranche within three months.
Second-order effects
- Rapid successive rounds — $51M, $106M, $225.5M, then $400M at a $4B valuation — push Olive into hypergrowth hiring and expansion commitments that its actual hospital deployment base must eventually justify.
- Competitors and successors in the same workflow-automation niche inherit both the proven demand signal and the cautionary pricing benchmark when they go to raise.
Third-order effects
- Olive's trajectory — from $222M raised to a 2022 layoff of roughly 31% of staff and a 2023 asset sale to Waystar and Humata Health — becomes the template case for how overcapitalized healthcare AI startups unwind, shifting later investors toward smaller, milestone-gated rounds like Hyro's $45M raise in 2025.
- If the pattern holds, hospital admin automation consolidates around acquirers such as Waystar rather than standalone venture-backed platforms, with buyers absorbing failed startups' technology instead of competing with it.
The trend: Healthcare administrative AI is cycling through a boom-and-consolidation phase in which venture capital floods workflow-automation startups faster than hospital adoption can absorb, ending in roll-ups by established health IT players.